AbbVie says Q2 EPS to include unfavorable impact of 17c
In a regulatory filing, AbbVie said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted